eli lilly glp-1 analog Lilly's Oral Therapy Foundayo (orforglipron) Is Now Available for Weight Loss FDA approves Foundayo, Eli Lilly's

Discover effective tips and strategies for Weight Loss that can help you achieve your goals confidently

GLP-1 RAs have demonstrated benefits in coronary artery disease, heart failure, blood pressure, and atrial fibrillation irrespective of type 2 diabetes mellitus status, with new possible applications in peripheral arterial disease

GLP-1s account for 23% of first line diabetes therapy in 2025 up from 3% in 2021 Since 2019, the American Diabetes Association (ADA) has revised its Standards of Care each year to expand the role of GLP-1 receptor agonists and SGLT2 inhibitors as first-line treatments for T2D2

He's standing by his wife.